Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also benefit from EGFR inhibitors (Merck & Co. / Eli Lilly’s Erbitux and Amgen’s Vectibix), which are recommended for first-line treatment of patients with left-sided tumors. Notably, additional targeted therapies for specific molecular subtypes have been developed: immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo and Yervoy) for MSI-high and/or MMR-deficient tumors; BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi) for metastatic colorectal cancer with a BRAF V600E mutation; and HER2-targeted agents in some markets (Chugai’s Perjeta and trastuzumab and Seagen’s Tukysa) for HER2-positive metastatic disease. Most therapies in late-stage development are intended to treat other genomic alterations (i.e., KRAS G12C mutation) or expand the immunotherapy-based approaches for treating MSS and/or pMMR tumors.
QUESTIONS ANSWERED
How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers?
What are interviewed experts’ views on current and emerging late-phase therapies, and what strategies are companies pursuing to secure uptake and share in the colorectal cancer market?
What are the key drivers and constraints in the colorectal cancer therapy market, and how will they change over the forecast period?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENTS
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast also features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Colorectal Cancer u2013 Key Findings u2013 August 2023
Key Updates
August 2023
May 2023
April 2023
January 2023
Q4 2022
November 2022
Q3 2022
September 2022
Market Outlook
Key findings
Market share of drug classes for colorectal cancer: 2022
Market share of drug classes for colorectal cancer: 2032
Drug-treatable population share and major-market sales share in colorectal cancer: 2022
Drug-treatable population share and major-market sales share in colorectal cancer: 2032
Population positioning of therapies in colorectal cancer
Colorectal cancer SWOT analysis
Market drivers and constraints
What factors are driving the market for colorectal cancer?
What factors are constraining the market for colorectal cancer?
Major-market sales of key drug classes for colorectal cancer: 2022-2032
Major-market sales of key drugs for colorectal cancer by brand / biosimilar: 2022-2032
Segment-specific trends
Patient-share dynamics of key players for stage III colon cancer in the United States: 2022-2032
Patient-share dynamics of key players for stage IV first-line left-sided BRAF wild-type RAS wild-type colorectal cancer in the United States: 2022-2032
Patient-share dynamics of key players for stage IV first-line right-sided BRAF wild-type RAS wild-type colorectal cancer in the United States: 2022-2032
Patient-share dynamics of key players for stage IV first-line BRAF wild-type RAS-mutant colorectal cancer in the United States: 2022-2032
Patient-share dynamics of key players for stage IV first-line BRAF-mutant RAS wild-type colorectal cancer in the United States: 2022-2032
Second-line metastatic colorectal cancer
Patient-share dynamics of key players for stage IV second-line left-sided BRAF wild-type RAS wild-type colorectal cancer in the United States: 2022-2032
Patient-share dynamics of key players for stage IV second-line right-sided BRAF wild-type RAS wild-type colorectal cancer in the United States: 2022-2032
Patient-share dynamics of key players for stage IV second-line BRAF wild-type RAS-mutant colorectal cancer in the United States: 2022-2032
Patient-share dynamics of key players for stage IV second-line BRAF-mutant RAS wild-type colorectal cancer in the United States: 2022-2032
Patient-share dynamics of key players for stage IV third- and fourth-line left-sided BRAF wild-type RAS wild-type colorectal cancer in the United States: 2022-2032
Patient-share dynamics of key players for stage IV third- and fourth-line right-sided BRAF wild-type RAS wild-type colorectal cancer in the United States: 2022-2032
Patient-share dynamics of key players for stage IV third- and fourth-line BRAF wild-type RAS-mutant colorectal cancer in the United States: 2022-2032
Patient-share dynamics of key players for stage IV third- and fourth-line BRAF-mutant RAS wild-type colorectal cancer in the United States: 2022-2032
Forecast
Market Forecast Assumptions
Market Forecast Dashboard
Etiology and Pathophysiology
Disease overview
Disease pathophysiology
Etiology
Risk factors for developing colorectal cancer
Pathophysiology
Proposed adenoma-carcinoma sequence model for colorectal cancer with chromosomal instability
Staging and classification
Staging of colorectal cancer
TNM classification of colorectal cancer
Modified Astler-Coller Dukes staging system vs. AJCC/UICC colorectal cancer (TNM) staging system
Symptoms according to tumor location in colorectal cancer
Screening for colorectal cancer
Prognostic factors in colorectal cancer
Key pathways and drug targets
Drug targets for colorectal cancer
Select genes reportedly involved in colorectal cancer
Epidemiology
Key findings
Key updates
Epidemiology populations
Disease definition
Methods
Sources used for diagnosed incidence of colorectal cancer
Diagnosed incident cases of colorectal cancer: 2022-2032
Disease definition
Methods
Sources used for the stage distribution of colorectal cancer
Diagnosed incident cases of colorectal cancer by stage distribution: 2022-2032
Definition
Methods
Sources used for recurrent incidence of colorectal cancer
Recurrent incident cases of colorectal cancer: 2022-2032
Colorectal cancer patient flow
Drug-treatable cases of colorectal cancer: 2022-2032
Drug-treated cases of colorectal cancer: 2022-2032
Current Treatment
Key findings
Treatment goals
Key endpoints used in clinical trials for colorectal cancer
Key current therapies
Overview
Mechanism of action of key current drug classes used for colorectal cancer
Current treatments used for colorectal cancer
Market events impacting the use of key current therapies in colorectal cancer
Key results from select clinical trials investigating bevacizumab for the treatment of colorectal cancer
Expert insight: bevacizumab
Key results from select clinical trials investigating Zaltrap for the treatment of colorectal cancer
Expert insight: Zaltrap
Key results from select clinical trials investigating Cyramza for the treatment of colorectal cancer
Ongoing clinical development of Cyramza
Key ongoing clinical trials of Cyramza in the treatment of colorectal cancer
Expert insight: Cyramza
Key results from select clinical trials investigating Stivarga for the treatment of colorectal cancer
Expert insight: Stivarga
Key results from select clinical trials investigating Erbitux for the treatment of colorectal cancer
Ongoing clinical development of Erbitux
Expert insight: Erbitux
Key results from select clinical trials investigating Vectibix for the treatment of colorectal cancer
Ongoing clinical development of Vectibix
Key ongoing clinical trials of Vectibix in the treatment of colorectal cancer
Expert insight: Vectibix
Key results from select clinical trials investigating Keytruda for the treatment of colorectal cancer
Ongoing clinical development of Keytruda
Key results from select clinical trials investigating Opdivo for the treatment of colorectal cancer
Ongoing clinical development of Opdivo
Key ongoing clinical trials of Opdivo in the treatment of colorectal cancer
Expert insight: Opdivo
Key results from select clinical trials investigating Braftovi for the treatment of colorectal cancer
Ongoing clinical development of Braftovi
Expert insight: Braftovi
Key results from select clinical trials investigating Lonsurf for the treatment of colorectal cancer
Ongoing clinical development of Lonsurf
Expert insight: Lonsurf
Key results from select clinical trials investigating Perjeta and trastuzumab combination therapy for the treatment of colorectal cancer
Ongoing clinical development of Perjeta and trastuzumab combination therapy
Expert insight: Perjeta plus trastuzumab
Key results from select clinical trials investigating Tukysa for the treatment of colorectal cancer
Ongoing clinical development of Tukysa
Key ongoing clinical trials of Tukysa in the treatment of colorectal cancer
Expert insight: Tukysa
Medical practice
Stage II/III colon cancer
Stage II/III rectal cancer
Treatment of colorectal cancer with resectable liver metastases
Second-line treatment of metastatic colorectal cancer
Third- and later-line treatment of metastatic colorectal cancer
Patient characteristics influencing drug selection in colorectal cancer
Treatment decision tree for stage II/III colon and rectal cancer: G7
Treatment decision tree for stage IV colorectal cancer: United States
Treatment decision tree for stage IV colorectal cancer: France, Germany, Italy, and Spain
Treatment decision tree for stage IV colorectal cancer: United Kingdom
Treatment decision tree for stage IV colorectal cancer: Japan
Unmet Need Overview
Current and future attainment of unmet needs in colorectal cancer
Top unmet needs in colorectal cancer: current and future attainment
Expert insights: unmet need in colorectal cancer
Drug Pipeline
Pipeline
Regulatory Milestones
Indication Comparison
Emerging Therapies
Key findings
Key emerging therapies
Key therapies in development for colorectal cancer
Estimated market authorization dates of key emerging therapies for the treatment of colorectal cancer
Key results from select clinical trials investigating fruquintinib for the treatment of colorectal cancer
Analysis of the clinical development program for fruquintinib
Expert insight: fruquintinib
Expectations for market authorization and sales opportunity of fruquintinib in colorectal cancer
Key results from select clinical trials investigating zanzalintinib for the treatment of colorectal cancer
Analysis of the clinical development program for zanzalintinib
Key ongoing clinical trials of zanzalintinib in the treatment of colorectal cancer
Expert insight: zanzalintinib
Expectations for market authorization and sales opportunity of zanzalintinib in colorectal cancer
Key results from select clinical trials investigating Krazati for the treatment of colorectal cancer
Analysis of the clinical development program for Krazati
Key ongoing clinical trials of Krazati in the treatment of colorectal cancer
Expert insight: Krazati
Expectations for the market authorization and sales opportunity of Krazati in colorectal cancer
Lumakras / Lumykras
Key results from select clinical trials investigating Lumakras / Lumykras for the treatment of colorectal cancer
Analysis of the clinical development program for Lumakras / Lumykras
Key ongoing clinical trials of Lumakras / Lumykras in the treatment of colorectal cancer
Expert insight: Lumakras / Lumykras
Expectations for market authorization and sales opportunity of Lumakras / Lumykras in colorectal cancer
Key results from select clinical trials investigating Tecentriq for the treatment of colorectal cancer
Analysis of the clinical development program for Tecentriq
Key ongoing clinical trials of Tecentriq in the treatment of colorectal cancer
Expert insight: Tecentriq
Expectations for market authorization and sales opportunity of Tecentriq in colorectal cancer
Key results from select clinical trials investigating the favezelimab / Keytruda fixed-dose combination for the treatment of colorectal cancer
Analysis of the clinical development program for favezelimab / Keytruda fixed-dose combination
Key ongoing clinical trials of favezelimab / Keytruda fixed-dose combination in the treatment of colorectal cancer
Expectations for the market authorization and sales opportunity for favezelimab / Keytruda fixed-dose combination in colorectal cancer
Analysis of the clinical development program for Opdualag
Key ongoing clinical trials of Opdualag in the treatment of colorectal cancer
Expert insight: Opdualag for the treatment of colorectal cancer
Expectations for market authorization and sales opportunity for Opdualag in colorectal cancer
Key results from select clinical trials investigating Jemperli for the treatment of colorectal cancer
Analysis of the clinical development program for Jemperli
Key ongoing clinical trials of Jemperli in the treatment of colorectal cancer
Expert insight: Jemperli
Expectations for market authorization and sales opportunity of Jemperli in colorectal cancer
Key results from select clinical trials investigating OncoVAX for the treatment of colorectal cancer
Analysis of the clinical development program for OncoVAX
Key ongoing clinical trials of OncoVAX in the treatment of colorectal cancer
Expert insight: OncoVAX
Expectations for market authorization and sales opportunity for OncoVAX in colorectal cancer
Analysis of the clinical development program for futuximab/modotuximab
Key ongoing clinical trials of futuximab/modotuximab in the treatment of colorectal cancer
Expert insight: Sym-004
Expectations for market authorization and sales opportunity for futuximab / modotuximab in colorectal cancer
Early-phase pipeline analysis
Select compounds in early-phase development for colorectal cancer
Access & Reimbursement Overview
Region-specific reimbursement practices
Key market access considerations in colorectal cancer: United States
General reimbursement environment: United States
Key market access considerations in colorectal cancer: EU5
General reimbursement environment: EU5
Key market access considerations in colorectal cancer: Japan
General reimbursement environment: Japan
Appendix
Colorectal cancer bibliography
Abbreviations
Laura Ramos
Laura Ramos Garcia, M.Sc., Ph.D., is an analyst on the Oncology team at Clarivate. During her training as a Ph.D., she gained in-depth knowledge in the field of cell death and inflammation. As a postdoctoral researcher, she worked on an emerging type of small molecule, PROTAC, that allows targeted protein degradation. She obtained her master of science degree in molecular medicine at Imperial College London and her doctorate in cancer biology at the Institute of Cancer Research (University of London).
Priyanka Sharma Markanda
Priyanka Sharma, M.B.A., Healthcare Research & Data Analyst, Oncology. Prior to joining this company, she was a knowledge management consultant with ZS Associates, where she was responsible for designing and conducting secondary research on disease markets and providing end-to-end support to pharmaceutical clients during products’ life cycle. She also worked at DelveInsight Business Research, where she conducted pharmaceutical market forecasting in multiple therapy areas for various clients. She holds a bachelor’s degree in pharmacy and an M.B.A. in pharmaceutical management from the University Institute of Applied Management Sciences at Panjab University in Chandigarh, India.